Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS4A5E
|
|||
| Drug Name |
SP 20202
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Clinical trial | [1] | |
| Company |
Sarfez Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mineralocorticoid receptor (MR) | Target Info | Antagonist | [1] |
| KEGG Pathway | Aldosterone-regulated sodium reabsorption | |||
| Pathwhiz Pathway | Kidney Function | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.